Literature DB >> 12646615

The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction.

BinuJoy John1, Brantley R Herrin, Chander Raman, Yan-ni Wang, Kevin R Bobbitt, Brian A Brody, Louis B Justement.   

Abstract

The B cell coreceptor CD22 plays an important role in regulating signal transduction via the B cell Ag receptor. Studies have shown that surface expression of CD22 can be modulated in response to binding of ligand (i.e., mAb). Thus, it is possible that alterations in the level of CD22 expression following binding of natural ligand(s) may affect its ability to modulate the Ag receptor signaling threshold at specific points during B cell development and differentiation. Therefore, it is important to delineate the physiologic mechanism by which CD22 expression is controlled. In the current study, yeast two-hybrid analysis was used to demonstrate that CD22 interacts with AP50, the medium chain subunit of the AP-2 complex, via tyrosine-based internalization motifs in its cytoplasmic domain. This interaction was further characterized using yeast two-hybrid analysis revealing that Tyr(843) and surrounding amino acids in the cytoplasmic tail of CD22 comprise the primary binding site for AP50. Subsequent studies using transfectant Jurkat cell lines expressing wild-type or mutant forms of CD22 demonstrated that either Tyr(843) or Tyr(863) is sufficient for mAb-mediated internalization of CD22 and that these motifs are involved in its interaction with the AP-2 complex, as determined by coprecipitation of alpha-adaptin. Finally, experiments were performed demonstrating that treatment of B cells with either intact anti-Ig Ab or F(ab')(2) blocks ligand-mediated internalization of CD22. In conclusion, these studies demonstrate that internalization of CD22 is dependent on its association with the AP-2 complex via tyrosine-based internalization motifs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646615     DOI: 10.4049/jimmunol.170.7.3534

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

2.  Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile.

Authors:  Ganna A Liubchenko; Holly C Appleberry; V Michael Holers; Nirmal K Banda; Van C Willis; Taras Lyubchenko
Journal:  J Autoimmun       Date:  2012-02-24       Impact factor: 7.094

Review 3.  Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.

Authors:  Binsah George; Hagop Kantarjian; Elias Jabbour; Nitin Jain
Journal:  Immunotherapy       Date:  2016-01-18       Impact factor: 4.196

4.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.

Authors:  Fatih M Uckun; Patricia Goodman; Hong Ma; Ilker Dibirdik; Sanjive Qazi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-14       Impact factor: 11.205

5.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 6.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

Review 7.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

8.  Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.

Authors:  Hiroaki Tateno; Hongyi Li; Melissa J Schur; Nicolai Bovin; Paul R Crocker; Warren W Wakarchuk; James C Paulson
Journal:  Mol Cell Biol       Date:  2007-06-11       Impact factor: 4.272

9.  Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.

Authors:  Kyle J Bednar; Elena Shanina; Romain Ballet; Edward P Connors; Shiteng Duan; Joana Juan; Britni M Arlian; Michael D Kulis; Eugene C Butcher; Wai-Ping Fung-Leung; Tadimeti S Rao; James C Paulson; Matthew S Macauley
Journal:  J Immunol       Date:  2017-09-29       Impact factor: 5.422

10.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.